Insulin was purchased from Life Technologies unless otherwise specified. Peptides were synthesized via Fmoc solid phase peptide synthesis. N,N-Diisopropylethylamine (DIEA), triisopropylsilane, L-ascorbic acid, acetic acid (AcOH), iodine, piperidine, methanol (MeOH), urea and dichloromethane (DCM) were purchased from Sigma-Aldrich and used directly. Fmocprotected amino acids and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) were purchased from Chem-Impex Int'l. Inc. Boc-Ser[FmocThr(tBu)] was purchased from AAPPTec. 2-Chlorotrityl chloride resin was purchased from ChemPep. Dimethylformamide (DMF), trifluoroacetic acid (TFA), acetonitrile (ACN) and ethyl ether were purchased from Fisher Scientific and used as supplied.
General procedure for A-chain
The syntheses of A-chains were conducted on 2-chlorotrityl chloride resin using a peptide synthesizer with a standard Fmoc/HATU/DIEA method. The resulting resin-bound A chain (0.1 mmol scale) was treated with 6.0 mL TFA solution containing 2.5% TIS, 2.5% H 2 O at rt, with gentle shaking for 2.0 hours. The resin was filtered off and the filtrate was precipitated by cold ether (40 mL). The precipitate was collected by centrifugation then washed with cold ether (40 mL x 3), and vacuum dried and purified by preparative C18 column. 67 mg of A2 (from 0.1 mmol starting resin) and 70 mg of A3 (from 0.10 mmol starting resin) were obtained after lyophilization, with a yield of 24% for A2 and 26% for A3.
General procedure for B chain
B-chain syntheses were conducted on 2-chlorotrityl chloride resin using a standard Fmoc/HATU/DIEA method. The first amino acids were synthesized manually. Cleavage was conducted by treating the resin (0.1 mmol scale) with 6.0 mL TFA solution that contained 2.5% TIS, 2.5% H 2 O and 15 equivalents of DTDP at rt, with shaking for 2.5 hours. The resin was filtered off; and the filtrate was precipitated with cold ether (45 mL). The precipitate was collected by centrifugation, and then washed with cold ether (45 mL x 3). Crude B chain was dissolved in 0.05% TFA containing aqueous acetonitrile (ACN/H 2 O: 50/50 vol/vol, 40 mL) and purified on a preparative C18 column. 87 mg of B2 (from 0.10 mmol starting resin) was obtained with a yield of 24%; 91 mg of B3 was obtained (from 0.10 mmol starting resin) with a yield of 25%; 78 mg of B4 (from 0.10 mmol starting resin) was obtained with a yield of 21%.
General procedure for preparation of analogs by two-step method
A chain and B chain were mixed in 6 M urea, 0.2 M NH 4 HCO 3 buffer (pH 7.5). The mixture was left at room temperature for 10 min. The resulting solution was purified on a preparative C18 column with a linear gradient from 25% aqueous ACN (0.1% TFA) to 50% aqueous ACN (0.1% TFA) over 45 min at a flow rate of 5 mL/min. A-B dimer eluted at around 30 min.
The lyophilized powder A-B dimer was dissolved in 33% aqueous acetic acid, and treated with a freshly prepared solution of iodine in MeOH (10 mg/mL). The resulting solution was gently agitated at rt for 20 min before the addition of 1 M ascorbic acid until the iodine color (purple) disappeared. The crude was purified on a preparative C18 column with a linear gradient from 20% aqueous ACN (0.1% TFA) to 50% aqueous ACN (0.1% TFA) over 45 min at a flow rate of 5 mL/min. The correctly folded analogs eluted as the earliest fraction by RP-HPLC at around 35 min.
Preparation of A22-B21-4SS-Ins:
A chain A2 (31 mg) and B chain B2 (52 mg) were mixed in 6 M urea, 0.2 M NH 4 HCO 3 buffer (pH 7.5, 4.6 mL). The mixture was left at rt for 10 min. The resulting solution was purified by preparative C18 column with a linear gradient from 25% aqueous ACN (0.1% TFA) to 50% aqueous ACN (0.1% TFA) over 45 min at a flow rate of 5 mL/min. 48 mg of dimer (A2+B2) was obtained with a yield of 68%.
The lyophilized powder A-B dimer (24 mg) was dissolved in 33% aqueous acetic acid (3.0 mL). It was treated with a freshly prepared solution of iodine in MeOH (10 mg/mL). The resulting solution was gently agitated at rt for 20 min before the addition of 1 M ascorbic acid until the iodine color (purple) disappeared. The crude was purified by preparative column with a linear gradient from 20% aqueous ACN (0.1% TFA) to 50% aqueous ACN (0.1% TFA) over 45 min at a flow rate of 5 mL/min. 2.5 mg of A22-B21-4SS-Ins was obtained with a yield of 11% from dimer (A2+B2), and a yield of 7.4% over two steps based on A2.
Preparation of A22-B22-4SS-Ins:
A chain A2 (30 mg) and B chain B3 (48 mg) were mixed in 6 M urea, 0.2 M NH 4 HCO 3 buffer (pH 7.5, 4.6 mL). The mixture was left at rt for 10 min. The resulting solution was purified by preparative column with a linear gradient from 25% aqueous ACN (0.1% TFA) to 50% aqueous ACN (0.1% TFA) over 45 min at a flow rate of 5 mL/min. 40 mg of dimer (A2+B3) was obtained with a yield of 60 %.
The lyophilized powder A-B dimer (22 mg) was dissolved in 33% aqueous acetic acid (3.0 mL). It was treated with a freshly prepared solution of iodine in MeOH (10 mg/mL). The resulting solution was gently agitated at rt for 20 min before the addition of 1 M ascorbic acid until the iodine color (purple) disappeared. The crude was purified by preparative column with a linear gradient from 20% aqueous ACN (0.1% TFA) to 50% aqueous ACN (0.1% TFA) over 45 min at a flow rate of 5 mL/min. 1.7 mg of A22-B21-4SS-Ins was obtained with a yield of 8.1% from dimer (A2+B3), and a yield of 4.9 % over two steps based on A2.
Preparation of A22-B23-4SS-Ins:
A chain A2 (30 mg) and B chain B4 (45 mg) were mixed in 6 M urea, 0.2 M NH 4 HCO 3 buffer (pH 7.5, 4.6 mL). The mixture was left at rt for 10 min. The resulting solution was purified by preparative column with a linear gradient from 25% aqueous ACN (0.1% TFA) to 50% aqueous ACN (0.1% TFA) over 45 min at a flow rate of 5 mL/min. 49mg of dimer (A2+B4) was obtained with a yield of 71%.
The lyophilized powder A-B dimer (25 mg) was dissolved in 33% aqueous acetic acid (3.0 mL). It was treated with a freshly prepared solution of iodine in MeOH (10 mg/mL). The resulting solution was gently agitated at rt for 20 min before the addition of 1 M ascorbic acid until the iodine color (purple) disappeared. The crude was purified by preparative column with a linear gradient from 20% aqueous ACN (0.1% TFA) to 50% aqueous ACN (0.1% TFA) over 45 min at a flow rate of 5 mL/min. 2.9 mg of A22-B23-4SS-Ins was obtained with a yield of 13 % from dimer (A2+B4), and a yield of 9.1 % over two steps based on A2.
Preparation of A21-B22-4SS-Ins:
A chain A3 (30 mg) and B chain B3 (48 mg) were mixed in 6 M urea, 0.2 M NH 4 HCO 3 buffer (pH 7.5, 4.6 mL). The mixture was left at rt for 10 min. The resulting solution was purified by preparative column with a linear gradient from 25% aqueous ACN (0.1% TFA) to 50% aqueous ACN (0.1% TFA) over 45 min at a flow rate of 5 mL/min. 37 mg of dimer (A3+B3) was obtained with a yield of 55%.
The lyophilized powder A-B dimer (25 mg) was dissolved in 33% aqueous acetic acid (3.0 mL). It was treated with a freshly prepared solution of iodine in MeOH (10 mg/mL). The resulting solution was gently agitated at rt for 20 min before the addition of 1 M ascorbic acid until the iodine color (purple) disappeared. The crude was purified by preparative column with a linear gradient from 20% aqueous ACN (0.1% TFA) to 50% aqueous ACN (0.1% TFA) over 45 min at a flow rate of 5 mL/min. 2.7 mg of A22-B23-4SS-Ins was obtained with a yield of 11.6 % from dimer (A3+B3), and a yield of 6.4 % over two steps based on A3. 
Insulin activity and aggregation assays
Phospho-AKT (Ser 473) cell-based assay: pAkt Ser473 levels were measured in a mouse fibroblast cell line, NIH 3T3, overexpressing human insulin receptor isoform B (IR-B). The cell line was cultured in DMEM (Sigma Aldrich) with 10% fetal bovine serum (Gibco), 100 U/mL penicillinstreptomycin (Thermo Fisher Scientific) and 2 mg/mL puromycin (Thermofisher Scientific). For each assay, 40,000 cells per well and 100 µl per well, were plated in a 96-well plates with culture media containing 1% FBS. 20 hours later, 50 µl of SCS-Insulin or native insulin was pipetted into each well after the removal of the original media. After a 30-min treatment, the insulin solution was removed and the HTRF pAkt Ser473 kit (Cisbio, Massachusetts, USA) was used to measure the intracellular level of pAkt Ser473. Briefly, the cells were first treated with cell lysis buffer (50 µl per well) for 1 h under mild shaking. 16 µL of cell lysate was then added to 4 µL of detecting reagent in a white 384-well plate. After 4 h incubation, the plate was read in a Synergy Neo plate reader (BioTek, Vermont, USA) and the data processed according to the manufacturer's protocol
Insulin aggregation assay:
The experiment was carried out according to a previously reported procedure by Webber et al. [1] . Insulin samples were dissolved in pH 7.4 PBS to a final concentration of 1 mg/mL. Samples were plated at 150 μL per well (n = 4/group) in a clear 96-well plate (Thermo Scientific Nunc) and sealed with optically clear and thermally stable seal. The plate was immediately placed into an Infinite M200 plate reader and shaken continuously at 37 °C. Absorbance readings at 540 nm were collected every 6 min for 100 h, and absorbance values were subsequently converted to transmittance.
Insulin tolerance test (ITT):
Insulin tolerance test (ITT) was performed on normal chow fed, 12-15 weeks old mice. On the day of experiment, the mice were fasted for 4-6 hours with the food removed and new bedding in the cages. The food was withdrawn for the entire experimental duration. The body weights and basal blood glucose concentrations (using Glucometer Contour nextEZ, Ascensia Diabetes Care US, Inc.) were measured. Following the basal measurements, the mice received intraperitoneal injections of 0.75 U/Kg body weight of either human insulin (Novolin R, ReliOn) or SCS-Ins dissolved in saline. The blood glucose concentrations were measured at 10, 20, 30 and 60 min after injection.
X-ray Crystallography
One milligram of lyophilized insulin was dissolved in 25 uL of 0.01 M HCl and diluted to a final concentration of 10 mg/mL in a buffer solution of 10 mM Tris pH 8.0 and 0.6% (w/v) zinc acetate. This solution was spin filtered for 1 minute at a relative centrifugal field of 2,348 g using a 0.22 μm cellulose acetate filter. Analogs were subjected to an insulin-focused, in-house crystallization screen that was based on experimental conditions reported in the PDB. Sitting-drop vapor diffusion plates were prepared with drops comprising 1 μL precipitant and 1 μL insulin solution. Crystals of the A22C-B22C insulin appeared in less than 10 minutes in well condition 500 mM sodium citrate, 8.5% (v/v) acetone, and 0.1% (v/v) phenol. Their typical dimensions were approximately 175 x 175 x 20 μm. Crystals were transferred briefly to a mixture of 30% glycerol and 70% well solution, and cryo-cooled by plunging into liquid nitrogen. Diffraction data were collected at 100 K on beam line 9-2 at the Stanford Synchrotron Radiation Lightsource. Data integration and scaling were performed with XDS[2] to a resolution limit of 1.6 Å. Initial phase calculations were done in AutoSol [3] using the anomalous signal of the insulin-bound zinc atoms. Subsequent rounds of modeling and refinement were done with COOT [4] and PHENIX [5] to a final R factor of 0.163 and R free of 0.196. Molecular graphics and RMSD calculations were performed with UCSF Chimera [6] . 
Isothermal Titration Calorimetry
To assess whether the addition of a disulfide bond near the insulin dimer interface affects the oligomerization of A22-B22-4SS-Ins, dissociation isothermal titration calorimetry (ITC) experiments were performed using human insulin and desoctapeptide insulin (DOI) as controls, essentially as described previously by Antolíková et al [7] . Lyophilized human insulin, DOI and A22-B22-4SS-Ins were reconstituted in 0.1 M glycine/HCl pH 2.5 to give a final volume of ~1 mL at an insulin concentration of 1 mM. The resulting insulin solutions were transferred to dialysis tubing and dialyzed against 300 mL of the glycine/HCl buffer for ~24 hours with three buffer exchanges. The final buffer exchange was performed least two hours before the insulins were recovered from the dialysis tubing. The concentration of the insulin analogs post-dialysis was determined by the absorbance at 280 nm using a NanoDrop 2000c spectrophotometer. ITC experiments were performed on a MicroCal iTC200 instrument, with each run comprising a total of twenty 2-uL injections with a 200-second interval. Human insulin was used as a dimer-forming positive control, and DOI was used as a non-dimerizing negative control. The first ITC experiments conducted on a given day were omitted due to large baseline shifts and high background signal. The ITC traces indicate that titration of A22-B22-4SS-Ins produced a similar heat effect to native insulin ( Figure S2 ), presumably indicating the formation of A22-B22-4SS-Ins dimers. K d values were calculated from the ITC data with Origin 7.0 (Table S2) Figure S3 . Measurement of A22-B22-4SS-Ins potency in IR-A or IR-B expressing 3T3 cells. The experimental condition is identical to the measurement using pAkt as an indication (Figure 2A ). However, phosphorylation of insulin receptor was used in this assay (Cisbio, US). We observed no preference for A22-B22-4SS-Ins to differentiate IR-A vs IR-B.
